← Back to Screener
Alzamend Neuro, Inc. Common Stock (ALZN)
Price$1.17
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-55.52%
Price vs S&P 500 (4W)1.28%
VGM Score21.88
Market Capitalization$4.53M
All Metrics
Book Value / Share (Quarterly)$0.57
P/TBV (Annual)2.19x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.62
Price vs S&P 500 (YTD)-45.55%
EPS (TTM)$-3.76
10-Day Avg Trading Volume0.09M
EPS Excl Extra (TTM)$-3.76
EPS (Annual)$-10.02
ROI (Annual)-113.78%
Cash / Share (Quarterly)$0.71
ROA (Last FY)-98.09%
EBITD / Share (TTM)$-2.77
ROE (5Y Avg)-296.65%
Cash Flow / Share (Annual)$-8.82
P/B Ratio2.07x
P/B Ratio (Quarterly)3.78x
Net Income / Employee (Annual)$-1,128,700
Net Interest Coverage (TTM)-249.41x
ROA (TTM)-140.39%
EPS Incl Extra (Annual)$-10.02
Current Ratio (Annual)6.58x
Quick Ratio (Quarterly)1.46x
3-Month Avg Trading Volume0.12M
52-Week Price Return-78.13%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.02
52-Week High$8.22
EPS Excl Extra (Annual)$-10.02
26-Week Price Return-39.59%
Quick Ratio (Annual)6.22x
13-Week Price Return-42.79%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.99x
Enterprise Value$1.81M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$5.07
3-Month Return Std Dev105.29%
Net Income / Employee (TTM)$-1,760,500
ROE (Last FY)-113.78%
Net Interest Coverage (Annual)-1007.87x
EPS Basic Excl Extra (Annual)$-10.02
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.76
ROI (TTM)-177.48%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.47
Price vs S&P 500 (52W)-106.33%
Year-to-Date Return-34.62%
5-Day Price Return5.31%
EPS Normalized (Annual)$-10.02
ROA (5Y Avg)-436.63%
Month-to-Date Return4.39%
Cash Flow / Share (TTM)$-2.35
EBITD / Share (Annual)$-9.86
ROI (5Y Avg)-289.38%
EPS Basic Excl Extra (TTM)$-3.76
P/B Ratio (Annual)1.10x
Book Value / Share (Annual)$5.10
Price vs S&P 500 (13W)-52.53%
Beta0.18x
Revenue / Share (TTM)$0.00
ROE (TTM)-177.48%
52-Week Low$0.84
mGradeD
vgmGradeD
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ALZNAlzamend Neuro, Inc. Common Stock | — | — | D | $1.17 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Alzamend Neuro is an early-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases and psychiatric disorders, with a focus on Alzheimer's disease. Its pipeline consists of AL001, a patented lithium-based ionic cocrystal technology, and AL002, a cell-based therapeutic vaccine designed to restore immune response against Alzheimer's.